turoctocog alfa

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
024620122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2015
Review
2015
BACKGROUND Turoctocog alfa (NovoEight(®)) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2015
Review
2015
Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine… (More)
Is this relevant?
Review
2014
Review
2014
Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
Review
2014
Review
2014
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor… (More)
Is this relevant?
2014
2014
Haemophilia and its treatment interfere with patients' life, so health-related quality of life (HRQoL) should be assessed when… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2014
Review
2014
Patients with hemophilia A lack functional coagulation factor VIII (FVIII), causing excessive spontaneous bleeding episodes and… (More)
Is this relevant?
2013
2013
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
Is this relevant?
2012
2012
The objective of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the new… (More)
Is this relevant?